Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26880294 | 0.86 | SIGMAR1 (0.49) | SIGMAR1HTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL20425551 | 0.79 | OPRM1 (0.38) | OPRM1HTR2AHTR2CCHRNA7CHRNB2 | |
| SCHEMBL2062499 | 0.79 | CHRNA7 (0.37) | SIGMAR1HTR2ACHRNA7CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL2061506 | 0.78 | HTR2A (0.37) | SIGMAR1HTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL24571166 | 0.71 | CHRNA7 (0.51) | SIGMAR1HTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL26880373 | 0.69 | CHRNB2 (0.73) | CHRNA7CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL30390683 | 0.69 | CHRNB2 (0.73) | CHRNA7CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL26880261 | 0.69 | CHRNB2 (0.73) | CHRNA7CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL26880281 | 0.69 | CHRNA7 (0.37) | SIGMAR1HTR2ACHRNA7CHRNB2CHRNA4 | |
| SCHEMBL26880279 | 0.69 | CHRNB2 (0.43) | HTR2ACHRNA7CHRNB2CHRNA4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373989-A1 | N-PHENYLAMINOCARBONYL PYRIDINO-, PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-11-23 | — | — | US | disclosed |
| US-20230373989-A1 | N-PHENYLAMINOCARBONYL PYRIDINO-, PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373989-A1 | N-PHENYLAMINOCARBONYL PYRIDINO-, PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | GPR65, GPR55, GPR68 | SIGMAR1 338/4885OPRM1 380/4885HTR2A 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.